Xspray Pharma Beheer

Beheer criteriumcontroles 2/4

De CEO Xspray Pharma is Per Andersson, benoemd in Jan2006, heeft een ambtstermijn van 18.75 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 3.74M, bestaande uit 70.5% salaris en 29.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.57% van de aandelen van het bedrijf, ter waarde SEK 9.38M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.9 jaar en 5.4 jaar.

Belangrijke informatie

Per Andersson

Algemeen directeur

SEK 3.7m

Totale compensatie

Percentage CEO-salaris	70.5%
Dienstverband CEO	18.8yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Per Andersson's beloning veranderd ten opzichte van Xspray Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-SEK 215m
Mar 31 2024	n/a	n/a	-SEK 213m
Dec 31 2023	SEK 4m	SEK 3m	-SEK 180m
Sep 30 2023	n/a	n/a	-SEK 180m
Jun 30 2023	n/a	n/a	-SEK 170m
Mar 31 2023	n/a	n/a	-SEK 148m
Dec 31 2022	SEK 4m	SEK 2m	-SEK 132m
Sep 30 2022	n/a	n/a	-SEK 128m
Jun 30 2022	n/a	n/a	-SEK 114m
Mar 31 2022	n/a	n/a	-SEK 102m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 97m
Sep 30 2021	n/a	n/a	-SEK 60m
Jun 30 2021	n/a	n/a	-SEK 57m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 52m
Sep 30 2020	n/a	n/a	-SEK 56m
Jun 30 2020	n/a	n/a	-SEK 55m
Mar 31 2020	n/a	n/a	-SEK 49m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 46m
Sep 30 2019	n/a	n/a	-SEK 41m
Jun 30 2019	n/a	n/a	-SEK 34m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 23m
Sep 30 2018	n/a	n/a	-SEK 17m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 8m
Dec 31 2017	SEK 2m	SEK 1m	-SEK 14m

Compensatie versus markt: De totale vergoeding ($USD 360.81K ) Per } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 734.17K ).

Compensatie versus inkomsten: De vergoeding van Per is gestegen terwijl het bedrijf verliesgevend is.

CEO

Per Andersson (57 yo)

18.8yrs

Tenure

SEK 3,743,000

Compensatie

Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Per Andersson	Chief Executive Officer	18.8yrs	SEK 3.74m	0.57% SEK 9.4m
Mustafa Demirbüker	Co-Founder and Science Director	no data	geen gegevens	geen gegevens
Niklas Adenborg	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Linda Glimberg	Chief Operating Officer	less than a year	geen gegevens	0.0053% SEK 87.0k
Kerstin Hasselgren	Senior Advisor & Head of IR	less than a year	geen gegevens	0.024% SEK 398.8k
Charlotta Liljebris	Senior Vice President of Research & Development	6.8yrs	geen gegevens	0.0089% SEK 145.1k
Edward Jordan	Chief Commercial Officer	1.1yrs	geen gegevens	geen gegevens
Anette Abrahamsson	Senior Vice President of Regulatory Affairs	less than a year	geen gegevens	0.0044% SEK 72.5k
Christer Hallgren	Senior Vice President of Intellectual Property	6.8yrs	geen gegevens	0.089% SEK 1.5m

0.9yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0GHZ wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Maris Hartmanis	Independent Director	9.8yrs	SEK 323.00k	0.092% SEK 1.5m
Carl-Johan Spak	Independent Director	9.8yrs	SEK 270.00k	geen gegevens
Anders Ekblom	Chairman	3.4yrs	SEK 510.00k	1.71% SEK 27.9m
Torbjörn Koivisto	Independent Director	7.8yrs	SEK 253.00k	geen gegevens
Christine Lind	Independent Director	5.4yrs	SEK 270.00k	geen gegevens
Anders Bladh	Director	3.4yrs	SEK 253.00k	2.49% SEK 40.7m
Robert Molander	Independent Director	2.4yrs	SEK 218.00k	0.030% SEK 483.5k

5.4yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0GHZ wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Xspray Pharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025

Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025

Director recently bought kr4.8m worth of stock

Director recently bought kr143k worth of stock

Insufficient new directors

Insufficient new directors

Recent updates

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Xspray Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 135.04904 million.

Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025

Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

Director recently bought kr4.8m worth of stock

Director recently bought kr143k worth of stock

Insufficient new directors

Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose

Insufficient new directors

Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

Xspray Pharma AB (publ) to Report Q2, 2024 Results on Aug 07, 2024

FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA

Xspray Pharma AB (Publ) Announces CFO Changes

Director recently bought kr2.1m worth of stock

Director recently bought kr395k worth of stock

Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage

Director recently bought kr5.0m worth of stock

New minor risk - Shareholder dilution

Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024

New major risk - Financial position

Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Forecast to breakeven in 2024

Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024

Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA

Forecast to breakeven in 2024

Xspray Pharma AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

Forecast to breakeven in 2024

Director recently bought kr2.6m worth of stock

Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer

Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors

Forecast to breakeven in 2024

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022

Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™

Forecast breakeven date pushed back to 2024

No longer forecast to breakeven

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd